Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

January 4, 2022

LungLife AI, Inc. - CPT® Code granted by American Medical Association

4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”) CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]

• Read More

November 22, 2021

LungLife AI Clinical Laboratory achieves CAP accreditation

19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]

• Read More

« Previous 1 … 32 33 34 35 36 … 41 Next »

More News